Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript May 7, 2024
Madrigal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-7.38 EPS, expectations were $-6.06. MDGL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Operator: Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals First Quarter 2024 Earnings Conference Call. [Operator Instructions]. As a...
